The term ‘no-deal Brexit’ has been used so much over the last year that many have become all but immune to its real meaning. The Clinical Services Journal examines what the impact of this may mean to the NHS.
At the beginning of 2019 GOV.UK published guidance on how medicines, medical devices and clinical trials would be regulated in the event of a ‘no-deal’ Brexit. This guidance was withdrawn on 17 July 2019 and has been replaced by ‘Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal’.
The technical notice provides information on the implications if the UK leaves the EU with ‘no-deal’ and offers guidance for continued planning.
Also included is an overarching framing notice explaining the government’s approach to preparing the UK for this outcome, in order to minimise disruption and ensure a smooth and orderly exit.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
Register
